# IgGenix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iggenix

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.iggenix.com
- Total disclosed funding: $76M
- Latest round: Series B (Feb 2, 2023)
- Investors on record: 6

## About

IgGenix, Inc., based in the US, is a biotechnology company focused on developing innovative monoclonal antibodies targeted at treating allergies and immunological diseases, with a specific emphasis on peanut allergies.Founded in 2019 and headquartered in South San Francisco, US, IgGenix, Inc. specializes in developing therapies for allergies. The company has raised a total of USD 40.00 mn through its most recent funding round, a Series B completed on February 2, 2023, led by Alexandria Venture Investments and including several other notable investors. Derek Croote founded the company, with Jessica Grossman serving as CEO.IgGenix, Inc. specializes in the discovery and development of innovative monoclonal antibodies aimed at addressing allergies and other immunological diseases. Their core product, IGNX001, is an injectable allergen-specific therapeutic designed to block the allergic cascade, particularly focusing on peanut allergies. Utilizing the proprietary SEQ SIFTER™ antibody discovery platform, the company identifies rare IgE-producing human B cells, enabling the engineering of high-affinity, allergen-specific IgG antibodies. Their products target both pediatric and adult populations suffering from food and environmental allergies, conducting clinical trials and observational studies across the United States, aimed at healthcare providers and patients dealing with life-threatening allergic reactions.IgGenix's revenue model is based on clinical trial partnerships and research collaborations to advance their therapeutic offerings. The company works with healthcare institutions and pharmaceutical partners to develop product candidates like IGNX001, structured around research agreements and potential licensing deals. Their focus on first-in-class antibody therapies positions them to receive funding through grants, equity investments, or milestone-based payments during development, with revenue generation dependent on successful clinical outcomes and market introductions of new therapeutics.Following the Series B funding round in February 2023, IgGenix, Inc. plans to utilize the USD 40.00 mn raised to expand its platform and advance its program to Phase 1 human clinical trials. The company is focused on launching IGNX001 and aims to expand its reach into additional markets, specifically targeting regions with high incidences of allergic diseases. The funding will support these initiatives, facilitating the development of new products and bolstering the company's presence in the allergy treatment landscape.

## Funding rounds

- Series B, Feb 2, 2023, $40M — Alexandria Venture Investments, Khosla Ventures, Eli Lilly & Company, Parker Ventures, AllerFund
- Series A, Jul 26, 2021, $26M — Alexandria Venture Investments, Khosla Ventures, ShangBay Capital, AllerFund
- Series A, Aug 4, 2020, $10M — Khosla Ventures, Parker Ventures

## Investors

- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series A, Series B
- Parker Ventures — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B
- ShangBay Capital (https://capitalatlas.ai/funds/shangbay-capital) — Series A
- AllerFund (https://capitalatlas.ai/funds/allerfund) — Series A, Series B
- Eli Lilly & Company — Series B